ReviewThe World Allergy Organization journal2023
Unanswered questions on the use of biologics in pediatric asthma.
Review in The World Allergy Organization journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Real-world effectiveness of asthma biologics by age of initiation and early-childhood risk factors.Annals of the American Thoracic Society · 2026Article
- Age-specific efficacy of biologics in severe asthma: a pediatric perspective.Frontiers in allergy · 2026Review
- Efficacy of Biologics in the Management of Pediatric Asthma: A Single-Center Retrospective Study.Cureus · 2026Article
- Prognostic utility of pre-biologic treatment correlates of childhood severe asthma exacerbation risk: Real world evidence.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025Article
- Real-world evidence on biologic use in paediatric asthma: there but not there yet?ERJ open research · 2025Article
- Severe Asthma in School-Age Children: An Updated Appraisal on Biological Options and Challenges in This Age Group.Children (Basel, Switzerland) · 2025Review
- T cell heterogeneity in asthma pathogenesis: from immunological mechanisms to biological targeted therapies.Frontiers in immunology · 2025Review
- Mepolizumab in Severe Pediatric Asthma: Certainties and Doubts through a Single-Center Experience and Review of the Literature.Children (Basel, Switzerland) · 2024Article
- An Updated Reappraisal of Dupilumab in Children and Adolescents with Severe Asthma.Children (Basel, Switzerland) · 2024Review
- Early Assessment of Efficacy and Safety of Biologics in Pediatric Allergic Diseases: Preliminary Results from a Prospective Real-World Study.Children (Basel, Switzerland) · 2024Article
- [Consensus document for Severe Asthma. 2025 Update].Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of biologic therapies for the management of asthma has been a revolutionary change in our capacity to manage this disease. Since the launch of omalizumab, several other biologics have been marketed or are close to being marketed, suggesting that a plethora of monoclonal antibodies can be expected in the coming years. This will facilitate the transition to the paradigm of personalized medicine, but on the other hand will decisively further complicate the choice of the most appropriate treatment, in the absence of reliable enough biological markers. For these reasons, along with the relatively short time of use with these treatments, there are recurrently arising questions for which there are not even moderately documented answers, and for which the only solution must be based, with all reservations, on the combination of indirect evidence and expertise. In this paper, we attempt to address such questions, providing relevant commentaries and considering the whole width of the evidence base.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.